Empowering the Immune System to Prevent and Treat Disease
VBI’s pipeline is comprised of vaccine and immunotherapeutic candidates developed by virus-like particle technologies to target two distinct, but often related, disease areas – infectious disease and oncology.
We prioritize the development of candidates for disease targets that are challenging, underserved, and where the human immune system, when powered and stimulated appropriately, can be a formidable opponent.
Our pipeline is unified in the mission to achieve better health for all.
Phase 3 Complete (US, EU, CAN)
Regulatory review for approval in U.S. and Europe ongoing
Approved for use and commercially-available in Israel as Sci-B-Vac®
A scientifically-differentiated approach to HBV vaccination, this vaccine candidate expresses the three surface antigens of the hepatitis B virus – pre-S1, pre-S2, and S – is adjuvanted with alum, and is manufactured in mammalian cells.
Published data suggest pre-S1 antigens induce neutralizing antibodies that block virus receptor binding, and T cell responses to pre-S1 and pre-S2 antigens can further boost responses to the S antigen.
Phase 1 (Complete)
VBI-1501 is a prophylactic eVLP vaccine candidate expressing a modified form of the gB antigen, gB-G.
Clinical data suggest that the modified gB-G antigen elicits both fibroblast and epithelial cell neutralization, with a qualitatively enhanced neutralizing response.
VBI-2901 is a multivalent pan-coronavirus vaccine candidate expressing a modified, optimized, pre-fusion form of the SARS-CoV-2 (COVID-19) spike antigen, as well as the SARS-CoV (SARS) and MERS-CoV (MERS) spike antigens on the surface of the eVLP particles.
Designed to increase breadth of immune reactivity, which may offer potential protection against emerging variants of COVID-19 and other coronaviruses. Coronaviruses are enveloped viruses by nature, making them prime targets for the eVLP vaccine technology.
VBI-2501 is a bivalent eVLP vaccine candidate consisting of a modified E glycoprotein (found on the surface of the Zika virus) and NS1 glycoprotein (secreted during Zika viral replication).
Preclinical data suggest that the modified E glycoprotein enhances neutralizing responses, and the NS1 T cell response enhances antibody response and protection.
Phase 1b/2a (ongoing)
VBI-2601 is an immunotherapeutic candidate that builds on the 3-antigen conformation of VBI’s prophylactic HBV vaccine candidate, but has been reformulated to enhance T cell responses.
VBI-2601 is being developed in collaboration with Brii Biosciences as part of a potential functional cure for chronic HBV infection.
Phase 1/2a (ongoing)
VBI-1901 is a bivalent eVLP cancer vaccine immunotherapeutic candidate that uses CMV as a foreign viral antigen approach to cancer treatment by expressing two highly-immunogenic CMV antigens – gB and pp65.
Scientific literature suggests that CMV infection is prevalent in multiple solid tumors, including GBM. VBI-1901 was co-administered with two adjuvants in the Phase 2a portion of the ongoing study: GM-CSF and GlaxoSmithKline’s AS01 adjuvant system.
Browse our library of publications to read more about our science and pipeline candidates.